Skip to main
SLNO

Soleno Therapeutics (SLNO) Stock Forecast & Price Target

Soleno Therapeutics (SLNO) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 13%
Buy 38%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Soleno Therapeutics Inc. is showing a positive financial trajectory, with preliminary unaudited full-year 2025 net revenue reported at $190 million from the U.S. launch of VYKAT XR in 2Q25, significantly exceeding original forecasts. The company is in a robust financial position with an expected cash reserve of approximately $500 million by the end of 2025, demonstrating strong profitability and positive cash flow. Additionally, VYKAT XR has shown strong early adoption, evidenced by 1,250 new patient start forms and a 12% discontinuation rate in line with expectations, suggesting a solid future growth potential in the rare diseases therapeutics market.

Bears say

Soleno Therapeutics faces significant challenges related to the market access and reimbursement obstacles affecting the uptake of its product candidate DCCR, which could hinder revenue generation. Additionally, the potential for earlier-than-expected generic erosion of the DCCR franchise, combined with difficulties in maximizing the product's value in international markets, raises concerns over the company's financial outlook. Risks are further compounded by the possibility of slower-than-anticipated U.S. commercialization progress, which may affect overall performance.

Soleno Therapeutics (SLNO) has been analyzed by 8 analysts, with a consensus rating of Buy. 13% of analysts recommend a Strong Buy, 38% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Soleno Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Soleno Therapeutics (SLNO) Forecast

Analysts have given Soleno Therapeutics (SLNO) a Buy based on their latest research and market trends.

According to 8 analysts, Soleno Therapeutics (SLNO) has a Buy consensus rating as of Apr 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $74.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $74.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Soleno Therapeutics (SLNO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.